Jung Min Moon

Prof. Jung Min Moon

Seoul National University Hospital, Seoul National University College of Medicine
+1

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2019 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
HSHosim Soh
Hosim Soh
JIJong Pil Im
Jong Pil Im
KHKyungdo Han
Kyungdo Han
SPSeona Park
Seona Park
SHSeung Wook Hong
Seung Wook Hong
JKJoo Sung Kim
Joo Sung Kim
Summary: Background: The relationships between lipid profiles and IBD remain elusive.Aim: To determine the association of IBD with serum lipid profiles.Methods: A nationwide population‐based study was performed using claims data from the Korean National Healthcare Insurance service. A total of 9 706 026 subjects undergoing medical check‐ups in 2009 were enrolled and followed up until 2016. Individuals who developed Crohn's disease (CD) or ulcerative colitis (UC) were identified during follow‐up. Adjusted hazard ratio (aHR) by age, sex, body mass index, cigarette smoking, alcohol drinking, exercise, income and underlying comorbidities was calculated to define the impact of serum lipid profiles on developing IBD.Results: During a median follow‐up of 7.3 years, IBD was detected in 7,058 (0.07%) individuals. Compared with the highest quartile of serum total cholesterol (TC) levels, lower TC levels were associated with higher incidence of CD (aHR: Q1, 2.52; Q2, 1.52; Q3, 1.27), but not UC. Lower serum LDL‐C levels were associated with higher incidence of CD (aHR: Q1, 1.92; Q2, 1.47; Q3, 1.22), but not UC. Moreover, lower serum HDL‐C levels were associated with higher incidence of CD (aHR: Q1, 2.49; Q2, 1.90; Q3, 1.43), but not UC. In contrast, lower serum triglyceride levels were associated with higher incidence of UC (aHR: Q1, 1.22; Q2, 1.19; Q3, 1.19), but not CD.Conclusions: Low serum TC, LDL‐C and HDL‐C levels were associated with CD. Low serum triglyceride levels were related to UC.

31 January 2023 in Intestinal Research
Verified
Journal Article
Open access
PDF file
SSSeung Yong Shin
Seung Yong Shin
YKYoung Kim
Young Kim
WKWon-Seok Kim
Won-Seok Kim
JMJung Min Moon
Jung Min Moon
KLKang-Moon Lee
Kang-Moon Lee
ODon behalf of the IBD Research Group of the Korean Association for the Study of Intestinal Diseases
on behalf of the IBD Research Group of the Korean Association for the Study of Intestinal Diseases
Background/Aims: The fecal microbiota of Korean patients with inflammatory bowel disease (IBD) was investigated with respect to disease phenotypes and taxonomic biomarkers for diagnosis and prognosis of IBD.Methods: Fecal samples from 70 ulcerative colitis (UC) patients, 39 Crohn’s disease (CD) patients, and 100 healthy control individuals (HC) were collected. The fecal samples were amplified via polymerase chain reaction and sequenced using Illumina MiSeq. The relationships between fecal bacteria and clinical phenotypes were analyzed using the EzBioCloud database and 16S microbiome pipeline.Results: The alpha-diversity of fecal bacteria was significantly lower in UC and CD (P<0.05) compared to that in HC. Bacterial community compositions in UC and CD were significantly different from that of HC according to Bray-Curtis dissimilarities, and there was also a difference between community composition in UC and CD (P=0.01). In UC, alpha-diversity was further decreased when the disease was more severe and the extent of disease was greater, and community composition significantly differed depending on the extent of the disease. We identified 9 biomarkers of severity and 6 biomarkers of the extent of UC. We also identified 5 biomarkers of active disease and 3 biomarkers of ileocolonic involvement in CD. Lachnospiraceae and Ruminococcus gnavus were biomarkers for better prognosis in CD.Conclusions: The fecal microbiota profiles of IBD patients were different from those of HC, and several bacterial taxa may be used as biomarkers to determine disease phenotypes and prognosis. These data may also help discover new therapeutic targets for IBD.

5 January 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
JMJung Min Moon
Jung Min Moon
HLHyun Jung Lee
Hyun Jung Lee
KHKyungdo Han
Kyungdo Han
DKDa Hye Kim
Da Hye Kim
SHSeung Wook Hong
Seung Wook Hong
JKJoo Sung Kim
Joo Sung Kim
Background: Although occult hemoglobin in feces is universally valued as a screening tool for colorectal cancer (CRC), only few studies investigated the clinical meaning of fecal immunochemical test (FIT) in other diseases. We evaluated the clinical utility of FIT in patients with cardiovascular diseases (namely, ischemic stroke and myocardial infarction [MI]). Methods and Results: Using the National Health Insurance database, participants (aged >50 years) with CRC screening records from 2009 to 2012 were screened and followed up. Subjects with a history of cardiovascular diseases and CRC were excluded. Ischemic stroke, MI, and other comorbidities were defined by International Classification of Diseases, Tenth Revision ( ICD‐10 ), codes. Age, sex, smoking, alcohol consumption, regular exercise, diabetes mellitus, hypertension, dyslipidemia, and body mass index were adjusted in a multivariate analysis. A total of 6 277 446 subjects were eligible for analysis. During the mean 6.79 years of follow‐up, 168 570 participants developed ischemic stroke, 105 983 developed MI, and 11 253 deaths were observed. A multivariate‐adjusted model revealed that the risk of ischemic stroke was higher in the FIT‐positive population (adjusted hazard ratio [HR], 1.09; 95% CI, 1.07–1.11). Similarly, FIT‐positive subjects were at an increased risk of MI (adjusted HR, 1.09; 95% CI, 1.06–1.12). Moreover, increased all‐cause mortality was observed in the FIT‐positive population (adjusted HR, 1.15; 95% CI, 1.07–1.23). The increased risk remained consistent in the stratified analysis on anemia and CRC status. Conclusions: Positive FIT findings were associated with ischemic stroke, MI, and mortality. Occult blood in feces may offer more clinical information than its well‐known conventional role in CRC screening.

19 December 2023 in Metabolites
Verified
Journal Article
Open access
PDF file
SKSeok-Young Kim
Seok-Young Kim
SSSeung Yong Shin
Seung Yong Shin
MSMaham Saeed
Maham Saeed
JRJi Eun Ryu
Ji Eun Ryu
JKJung-Seop Kim
Jung-Seop Kim
HCHyung-Kyoon Choi
Hyung-Kyoon Choi
We aimed to develop prediction models for clinical remission associated with adalimumab treatment in patients with ulcerative colitis (UC) using Fourier transform–infrared (FT–IR) spectroscopy coupled with machine learning (ML) algorithms. This prospective, observational, multicenter study enrolled 62 UC patients and 30 healthy controls. The patients were treated with adalimumab for 56 weeks, and clinical remission was evaluated using the Mayo score. Baseline fecal samples were collected and analyzed using FT–IR spectroscopy. Various data preprocessing methods were applied, and prediction models were established by 10-fold cross-validation using various ML methods. Orthogonal partial least squares–discriminant analysis (OPLS–DA) showed a clear separation of healthy controls and UC patients, applying area normalization and Pareto scaling. OPLS–DA models predicting short- and long-term remission (8 and 56 weeks) yielded area-under-the-curve values of 0.76 and 0.75, respectively. Logistic regression and a nonlinear support vector machine were selected as the best prediction models for short- and long-term remission, respectively (accuracy of 0.99). In external validation, prediction models for short-term (logistic regression) and long-term (decision tree) remission performed well, with accuracy values of 0.73 and 0.82, respectively. This was the first study to develop prediction models for clinical remission associated with adalimumab treatment in UC patients by fecal analysis using FT–IR spectroscopy coupled with ML algorithms. Logistic regression, nonlinear support vector machines, and decision tree were suggested as the optimal prediction models for remission, and these were noninvasive, simple, inexpensive, and fast analyses that could be applied to personalized treatments.

10 December 2020 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
JMJung Min Moon
Jung Min Moon
JIJong Pil Im
Jong Pil Im
DKDonghee Kim
Donghee Kim
YHYoo Min Han
Yoo Min Han
HSHosim Soh
Hosim Soh
JKJoo Sung Kim
Joo Sung Kim

16 February 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SPSeona Park
Seona Park
HLHyun Jung Lee
Hyun Jung Lee
KHKyungdo Han
Kyungdo Han
HSHosim Soh
Hosim Soh
JMJung Min Moon
Jung Min Moon
JKJoo Sung Kim
Joo Sung Kim
Background and Aims: The impact of proteinuria and its severity on the incidence of inflammatory bowel disease (IBD) has not yet been studied. We aimed to determine the association between proteinuria measured by urine dipstick tests and the development of IBD. Methods: This nationwide population-based study was conducted using the Korean National Health Insurance Service (NHIS) database. A total of 9,917,400 people aged 20 years or older who had undergone a national health examination conducted by the NHIS in 2009 were followed up until 2017. The study population was classified into four groups—negative, trace, 1+, and ≥ 2+—according to the degree of proteinuria measured by the urine dipstick test. The primary endpoint was newly diagnosed IBD, Crohn’s disease (CD), or ulcerative colitis (UC) during the follow-up period. Results: Compared with the dipstick-negative group, the incidence of CD significantly increased according to the degree of proteinuria (adjusted hazard ratio [aHR] with 95% confidence interval [CI], 1.01 [0.703–1.451], 1.515 [1.058–2.162], and 2.053 [1.301–3.24] in the trace, 1+, and ≥ 2+ dipstick groups, respectively; p for trend 0.007). However, there was no significant difference in the incidence of UC according to the degree of proteinuria (aHR with 95% CI, 1.12 [0.949–1.323], 0.947 [0.764–1.174], and 1.009 [0.741–1.373] in the trace, 1+, and ≥ 2+ dipstick groups, respectively; p for trend 0.722). In the subgroup analysis, dipstick-positive proteinuria independently increased the incidence of CD regardless of the subgroup. However, dipstick-positive proteinuria was associated with the risk of UC in those with diabetes mellitus and not in those without diabetes mellitus (aHR, 1.527 vs. 0.846; interaction p-value 0.004). The risk of CD was increased or decreased according to proteinuria changes but not associated with the risk of UC. Conclusion: Proteinuria, measured by the dipstick test, is strongly associated with the development of CD.